AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance demonstrated the overall strength of its immunology franchise.